Pharmacologic Substance
Novartis Achieves Success in Two Phase III Trials for Rare Kidney Diseases, Eyes Regulatory Submissions
Novartis, Phase III trials, Rare kidney diseases, IgA nephropathy, C3 glomerulopathy, Regulatory submissions
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment
AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup
AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound
** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO
Pharmaceutical Giants Secure Victory in Initial Zantac Lawsuit
Zantac, GSK, Boehringer Ingelheim, lawsuit, victory, heartburn medication, ranitidine, NDMA
Semaglutide Significantly Improves Cardiovascular Health and Reduces Mortality Risk in Kidney Disease Patients, Novo Reports
Semaglutide, Novo, cardiovascular health, kidney disease, mortality risk, clinical trial
Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization
biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.
Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China
Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials